Loading clinical trials...
Loading clinical trials...
A Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Cross-over Phase 2 Study of Continuous 5-Hour Intravenous Infusions of BMS-986231 in Patients With Heart Failure and Impaired Systolic Function
The purpose of this study is to evaluate the effects of BMS-986231 on systolic and diastolic parameters in patients with heart failure and low ejection fraction.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Orange County Research Center
Tustin, California, United States
Northwestern Medicine
Chicago, Illinois, United States
Indiana University School of Medicine-Indianapolis
Indianapolis, Indiana, United States
Brigham and Womens Hospital
Boston, Massachusetts, United States
Duke Advanced Heart and Lung Failure Clinic
Durham, North Carolina, United States
Inova Heart and Vascular Institute
Falls Church, Virginia, United States
Local Institution
Nagoya, Aichi-ken, Japan
Local Institution
Kawasaki, Kanagawa, Japan
Local Institution
Suita-shi, Osaka, Japan
Local Institution
Groiningen, Netherlands
Start Date
November 30, 2017
Primary Completion Date
May 10, 2019
Completion Date
May 10, 2019
Last Updated
July 27, 2020
49
ACTUAL participants
HNO Donor
DRUG
Nitroglycerin (NTG)
DRUG
Placebo
OTHER
Lead Sponsor
Bristol-Myers Squibb
NCT07484009
NCT07191730
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions